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Available online 16 February 2017Currently, drug delivery to the posterior eye segment relies on intravitreal injections of therapeutics. This ap-
proach requires frequent injections and does not guarantee drug delivery to intracellular targets. Controlled re-
lease systems and nanoparticles are being investigated to mitigate these challenges but most of these
approaches lack translational success to the clinics. In our present study, we report a peptide-based delivery sys-
tem that utilizes enzyme assisted cleavable linkers to release conjugated cargowithin the retinal pigment epithe-
lial (RPE) cells. Peptide linkers with differential cleavage rates were developed and tested in the vitreous humor,
RPE cell homogenates and intact RPE cells. Selected peptide linkers were conjugated to cell penetrating peptides
and D-peptide cargoes. The peptide-based delivery systems were non-toxic to the RPE cells, chemically stable in
porcine vitreous and delivered cargo prototypes (hydrophobic & hydrophilic) to the RPE cells. Importantly, we
show quantitatively with LC/MS analytics that the intracellular cargo release is controlled by the sequence of
the peptide linker. The controlled cleavage of the peptide linkers is not only a useful strategy for intracellular
drug delivery to the RPE targets but might also be useful in utilizing the RPE cells as mediators of drug delivery
to intracellular targets and surrounding tissues (such as neural retina and choroid).








Drug delivery to the posterior segment of the eye is a major chal-
lenge. This is due to the unique anatomy and physiological barriers in
the eye. Topical eye drop administration does not deliver adequate
drug concentrations to the retina whereas systemic administration is
hampered by the blood retina-barrier [1]. For these reasons, invasive
intravitreal injections are commonly used to deliver Fab-fragments,
IgG based antibodies, corticosteroids and soluble receptors in the treat-
ment of the posterior segment of the eye [2–5]. Sub-conjunctival,
suprachoroidal, and periocular routes have been proposed as alterna-
tives to intravitreal injections [6–9], but these approaches do not result
in effective retinal drug delivery [10]. In the case of the sub-retinal route,
the technique is too demanding for wide clinical use [11].
New retinal therapeutics are being widely explored as most retinal
diseases are still without effective treatment. Retinal drug discovery in-
cludes smallmolecular drugs, proteins andnucleotide-based geneprod-
ucts. In many cases, the drug targets are located in intracellular
compartments [12,13]. For example, pathological changes (protein(M. Bhattacharya).aggregation, oxidative stress, inflammation) take place within the reti-
nal pigment epithelial cells in diseases such as the dry form of age-relat-
ed macular degeneration [14–16]. Unfortunately, most nucleotide and
peptide-based compounds have poor permeability into the target cells
[17,18]. Intracellular drug delivery systems are needed for the develop-
ment of effective retinal treatments. Nanoparticle based formulations,
such as liposomes and polymeric nanoparticles have been used to aug-
ment the intracellular delivery of biologicals [19–21] but intracellular
drug release from particulate based systems is often poorly controlled
[12,22]. Furthermore, access of the nanoparticles to target cell layers
in the retina is also problematic, especially in the case of cationic nano-
particles that are usually used for intracellular delivery of DNA and RNA
based drugs [23]. These formulations tend to stick to the vitreous or
inner limiting membrane of the retina [24,25].
The major challenges in the retinal drug delivery are (a) prolonga-
tion of the intravitreal dosing interval; (b) intracellular delivery of pep-
tide and nucleotide based drugs (e.g. oligonucleotides, proteins); (c)
replacement of intravitreal injections with less invasive modes of drug
delivery. Clinical VEGF-A antagonists (treatment of wet AMD) such as
IgG antibodies (bevacizumab), Fab-fragment (ranibizumab), and solu-
ble VEGF receptor (aflibercept) [26–28] are injected intravitreally once
a month or bi-monthly. Most other drugs (e.g. small molecules) cannot
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from the posterior eye segment necessitating injections at too short in-
tervals to be clinically feasible [29]. To mitigate such issues, controlled
drug delivery systems are verymuch desired for intravitreal treatments.
Currently investigated systems include polymeric implants, micro-
spheres and encapsulated cells [30–33]. Intravitreal delivery of implants
and microspheres is invasive and material toxicity hampers the devel-
opment of many systems [34]. Furthermore, these systems lack the in-
herent ability to deliver the cargo into the target cells.
We aimed to generate a peptide-based drug delivery system that is
based on adequate intracellular access and controlled cargo release
within the RPE cells. The delivery system is intended for intravitreal ad-
ministration. Other possible routes of delivery could be suprachoroidal
and periocular. Furthering on the idea of using endogenous components
to trigger intracellular release, we have explored enzyme-assisted ‘pep-
tide-based cleavable linkers’ (PCLs) to control cargo release within the
RPE cells. Cathepsin D, a lysosomal enzyme, has relatively high expres-
sion levels in RPE cells [35]. Consequently, peptide sequences sensitive
to cathepsin D were selected as PCLs. The N-terminus of the PCLs was
conjugated with cell penetrating peptides (CPPs) and D-pentapeptide
cargoes were conjugated at the C-terminus. CPPs are charged peptide
sequences capable of intracellular delivery of molecular cargo [36,37].
D-Pentapeptide cargoes were chosen for ease of synthesis, resistance
to proteolytic cleavage, convenient detection and easy manipulation of
the sequence to modify physicochemical properties of the cargo proto-
types (hydrophobic/hydrophilic). Controlled drug delivery from the in-
tracellular depots was demonstrated and quantitated with LC/MS. The
design and strategy of the approach are depicted in Scheme 1.2. Materials and methods
2.1. Peptide synthesis
All the PCLs containing both natural and unnatural amino acids
(Tables 1, 3); CPP-PCL chimeras (Scheme 2); cargo conjugates (CCs,
Table 2) and labeled cargo fragments (Table 2) used in this study
were synthesized by Peptide Synthetics-Peptide Protein Research Ltd.
(Hampshire, UK). In general, the peptides were synthesized using
solid phase peptide synthesis via standard Fmoc chemistry [38] in a
0.1 mmol scale using a Symphony automated peptide synthesizer (Pro-
tein Technologies, Arizona). Internally quenched oligopeptide se-
quences (Scheme 3) contained the fluorescence resonance energy
(FRET) pair EDANS/Dabcyl (DABCYL: 4-{[4-(dimethyl amino) phenyl]
azo} benzoic acid; EDANS: 5-[(2-aminoethyl) amino] naphthalene-1-Scheme 1. Overview of design and experimental setsulfonic acid). Spectral properties of EDANS/Dabcyl are shown in Fig.
S1 (Supplementary material). For FRET, the donor and acceptor moie-
ties must be in close proximity, typically 10–100 Å. The typical förster
radius (R0) value for EDANS/Dabcyl pair is 33 Å [39]. Considering the
axial distance between the alpha carbon atoms of two adjacent residues
to be about 3.5 Å; EDANS and Dabcyl moieties were placed 10–13 resi-
dues apart in all the oligopeptides (PCLs: Table 1; PCL analogs: Table 3;
CPP-PCL chimeras: Scheme 2). The peptides were purified via Prep RP-
HPLC using a Varian system comprising of two 210 pumps, a 320 UV
dual wavelength detector andVarian star software employing gradients
between the mobile phases, water (0.1% TFA) and acetonitrile (0.1%
TFA); equipped with a C18 Gemini Axia column (5 μm particle size,
110 Å pore size, 200mmby 21mm, Phenomenex). Fractions containing
the desired peptide as indicated by UV absorbance were collectedman-
ually; analyzed by LC-MS (Agilent 1100 systems equipped with Aeris
core shell column, 100A 150 × 4.6 mm) to determine the purity and
freeze dried.2.2. FRET-based peptide cleavage assay
An assay to determine the cleavage rates of the synthesized
oligopeptides with FRET pair EDANS/Dabcyl was carried out using ei-
ther purified enzyme (cathepsin D) or ARPE-19 cell lysate at
oligopeptide concentration of 20 μM. The assay was performed in 96-
well black plates in 0.1 M sodium acetate buffer pH 4.0 (100 μl). Briefly,
ARPE-19 cells were lysed using lysis buffer (Biovision, California, USA)
and lysates were centrifuged at 10,000g for 10 min at 4 °C and the su-
pernatant was used for the enzymatic assay. Oligopeptide sequences
containing the FRET pair were mixed with cell lysate supernatant and
the reaction mixture was incubated at 37 °C. The substrate cleavage
wasmonitored bymeasuring the fluorescence as a function of time (ex-
citation 340 nm; emission 490 nm) using a microplate fluorescence
reader (Varioskan Flash, ThermoScientific). 100% cleavagewas assessed
based on the fluorescence obtained from an equimolar free concentra-
tion of EDANS (the chromophore present in oligopeptides).2.3. Cell culture
ARPE-19 cells (human retinal pigment epithelial cell line, ATCC CRL-
2302) were cultured in Dulbecco's Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F-12) supplemented with 10% fetal bovine
serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM
L-glutamine (Gibco). The cells were cultured in a T-75 flask at 37 °C in aup of the peptide based cargo delivery system.
Table 1
Peptide based cleavable linkers (PCLs) screened for cathepsin D enzymatic assay.
PCL sequencesa
P8 P7 P6 P5 P4 P3 P2 P1 P1′ P2′ P3′ P4′ P5′ P6′ P7′
PCL1 K* G K P I L F F R L K r E*
PCL2 K** G S K P I L F F R L K r E*
PCL3 K* G S K P I L F F R L K r E*
PCL4 K** P I L F F R L G K E*
PCL5 K* P I L F F R L G K E*
PCL6 K** G S P I L F F R L G K E*
PCL7 K** G S P I L F F(4NO2) R L E*
PCL8 K** G S P I V F F(4NO2) R L E*
PCL9 K** G S K N L I P R L E*
PCL10 K** G S A L I S W I K R E*
E⁎ refers to fluorescence donor EDANS (5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid) attached to glutamic acid side chain.
K⁎ and K⁎⁎ denotes fluorescence quencher Dabcyl (4-{[4-(dimethyl amino) phenyl] azo} benzoic acid) amidated to lysine side chain and the N-terminus, respectively. All peptides were
synthesized as carboxamide (CONH2) at the C-terminus.
a Lower case single letter amino acid abbreviation denotes D-amino acid.
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reached 80% confluency. The culturemedia were changed twice aweek.
To obtain polarized and differentiated RPE cells (blood-retina-barri-
ermodel), ARPE-19 cells were cultured on Transwell filters as described
earlier [40]. Briefly, cells were seeded at a density of 1.6 × 105 cells/cm2
on laminin coated Transwell permeable supports (surface area
4.67 cm2, pore size 0.4 μm, Corning Life Sciences, Corning, NY, USA)
and differentiated for 4 weeks. The basic filter culture medium (also re-
ferred to as basic filter medium) contained only 1% FBS but was other-
wise same as above. The cells were maintained at 37 °C in 7% CO2
atmosphere. Trans-epithelial electrical resistance (TER) of the ARPE
monolayer was measured by Endohm™ starting from the second
week of Transwell culture. Cell passages from 28 to 34 were used.Scheme 2. CPPs conjugated with PCLs. aLower case single letter amino acid abbreviation
refers to D-amino acid. E⁎ denotes fluorescence donor EDANS (5-[(2-aminoethyl) amino]
naphthalene-1-sulfonic acid) attached to the glutamic acid side chain and K⁎ refers to
Dabcyl (4-{[4-(dimethyl amino) phenyl] azo} benzoic acid) amidated to the lysine side
chain.2.4. Cytotoxicity assay
Cytotoxicity of the oligopeptide constructs was evaluated usingMTT
assay. In this method, NADPH-dependent cellular oxidoreductase en-
zyme reduces the tetrazolium dye MTT 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide to insoluble formazan in the mito-
chondria of living cells. The assay was performed as previously de-
scribed [41]. Briefly, the cells were seeded in 96-well plates at a
density of 20,000 cells per well in 150 μl growth medium. After over-
night incubation, the cells were washed with PBS. Peptides at various
concentrations (0.032–100 μM) in complete cell growth medium
(100 μl) were added to each well for incubation (5 h at 37 °C; 5%
CO2). Poly-L-Lysine (PLL) treated and untreated cells served as negative
and positive control respectively. After incubation, themedia containing
peptides was aspirated, the wells were washed with PBS and 150 μl of
growth medium was added to the cells. Then, after 24 h incubation,
the cells were washed with PBS. A mixture of 90 μl of complete growth
media and 10 μl of 5 mg/ml of MTT solution was added to all the wells.
The plateswere incubated for 4 h at 37 °C. After incubation, 100 μl of 10%
sodium dodecyl sulfate (Merck) in 0.01 M HCl (Sigma-Aldrich) was
added to thewells to solubilize formazan crystals followed by overnight
incubation at 37 °C. Formazan was quantified bymeasuring absorbance
at 570 nm using a spectral scanningmultimode plate reader (Varioskan
Flash, Thermo Scientific). Cell viability of the treated cellswas compared
to the untreated control cells.2.5. Cell uptake studies
Cellular uptake of oligopeptide constructs was determined by flow
cytometry. One day before the experiment, ARPE-19 cells were seeded
in 6-well plates at a density of 400,000 cells/well in 2 ml growth medi-
um. Prior to the uptake studies, the cells were rinsed twice with 2 ml
HBSS buffer (Gibco, supplemented with 10 mM Hepes, pH 7.4) and
equilibrated in the same buffer for 30 min at 37 °C. The cells were
then treated with FRET pair containing oligopeptide constructs (5 μM)
for 1 h at 37 °C. After washing the cultures thrice with 2 ml HBSS buffer
(containing 10 mM Hepes pH 7.4), the cells were detached from the
wells using 0.25% trypsin/EDTA (Tryplex®). The cells were harvested
and centrifuged at 1000 rpm for 5 min, and the cell pellet was gently
suspended in 1 ml HBSS buffer, transferred to FACS tubes and immedi-
ately analyzed by flow cytometry (BD FACS Aria II Cell sorter) with a
near UV laser (375 nm) as the excitation source. Fluorescence of
EDANS was recorded with a 450/20 band-pass filter. For each sample,
10,000 events were collected. Each experimentwas performed in tripli-
cate. Control cells without exposure to the oligopeptides were visual-
ized on a forward angle light scatter (FSC) versus a 90° angle side
scatter (SSC) display. The major cell population was gated and only
Table 2
Cargo conjugates (CCs) and corresponding fragments after intracellular cleavage. Fragments were detected by LC-MS. The CPP, PCL and cargo sequences are shown in blue, green and red,
respectively. A short flexible linker (Gly-Gly-Ser), shown in black, was introduced in between the CPP and PCL sequences.
Cargo  







CC-1 KGKPILFFRLKr-fwpVl rfwpVl-NH2 815.4 816.4
KrfwpVl-NH2 943.5 944.5
CC-2 KGKPILFFRLKr-ynaVl rynaVl-NH2 733.4 734.4
KrynaVl-NH2 861.5 862.5
CC-3 GRKKRRQRRPPQGGSKGKPILFFRLKr-fwpVl rfwpVl-NH2 815.4 816.4
KrfwpVl-NH2 943.5 944.5
CC-4 GRKKRRQRRPPQGGSKGKPILFFRLKr-ynaVl rynaVl-NH2 733.4 734.4
KrynaVl-NH2 861.5 862.5
CC-5 GRKKRRQRRPPQGGSKGSALISWIKR-fwpVl rfwpVl-NH2 815.4 816.4
KrfwpVl-NH2 943.5 944.5
CC-6 GRKKRRQRRPPQGGSKGSALISWIKR-ynaVl rynaVl-NH2 733.4 734.4
KrynaVl-NH2 861.5 862.5
For interpretation of the references to colour in this table note, the reader is referred to the web version of this article.
aLower case single letter amino acid abbreviation refers to D-amino acid. All CCs were synthesized as acetylation at the N-terminal and carboxamide (CONH2) at the C-terminus.
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analyzed using FACS Diva version 6.1.3 (BD).2.6. In vitro stability of oligopeptides in porcine vitreous
Stability of the oligopeptides against enzymatic degradation in por-
cine vitreous was determined. Porcine eyes were procured from a
local slaughterhouse. The eyes were kept on ice bath during the isola-
tion of vitreous humor. The eyes were first cleaned of extra-ocular ma-
terial and dipped in 70%ethanol. Then, the eyeswere opened by incision
with a dissecting knife and the clear vitreous humor was separated
gently from neural retina. Isolated vitreous humor was homogenized,
centrifuged (3200g) for 1 h at+4 °C and the supernatantwas sterile-fil-
tered using a 0.22 μm filter to remove cellular debris andmicrobial con-
tamination. The vitreous was stored at −80 °C. For stability studies,
oligopeptides with FRET pair were added to the porcine vitreous
humor in a 96 well black plate. The mixture was incubated at 37 °C
and the cleavage of the oligopeptide was monitored by measuring the
EDANS fluorescence as a function of time (excitation 340 nm; emission
490 nm) using amicroplate fluorescence reader (Varioskan Flash, Ther-
mo Scientific).Scheme 3. FRET based screening assay with EDANS/Dabcyl as the donor/acceptor pair. Fluores2.7. Quantitative cargo release in the RPE cells
Two D-pentapeptide sequences, fwpVl (log D = +2.0) and ynaVl
(logD=−2.0)were chosen as cargoes that are prototypes of smallmo-
lecular hydrophobic and hydrophilic drugs, respectively (Table 2). The
cargoes were conjugated to the C-terminal of CPP-PCL chimeras.
Firstly, cargo releasewas estimated using sub-confluent ARPE-19 cells
that were cultured on wells. Experiments were performed 48 h after
seeding of the ARPE-19 cells on 6-well plates at a density of 500,000
cells/well. At that time the cells achieved a sub-confluent monolayer (ap-
proximately 80–90% confluence). Prior to the experiment, the cells were
rinsed twice with PBS (Gibco). Cargo containing oligopeptide solutions
were freshly prepared in complete growth medium (DMEM/F-12; sup-
plemented with 100 U/ml streptomycin/penicillin and 2 mM L-gluta-
mine). The cells were then incubated with the oligopeptides (5 μM/
well) for 1 h at 37 °C. Subsequently, the cells were washed three times
with PBS and detached from the bottom of thewells with TrypLE Express
Enzyme (Gibco). The number of cells harvested fromeachwellwas deter-
mined. The cells were lysed by addition of cell lysis buffer (Biovision)
following the manufacturer's instructions. Clear cell lysate obtained
from each well was transferred into low binding eppendorf tubes
(Eppendorf®) and stored on ice before LC-MS analyses.cence is detected upon cleavage of the peptide scissile bond by the enzyme, cathepsin D.
Table 3
Sequences of PCL analogs.
P7 P6 P5 P4 P3 P2 P1 P1′ P2′ P3′ P4′ P5′ P6′ P7′
PCL1-a K* G K P I L F F R L K Cit E*
PCL1-b K* G K P I L 1-Nal 1-Nal R L K r E*
PCL1-c K* G K P I L W W R L K R E*
PCL8-a K** G S P I V F F(4NO2) R L E R E*
PCL10-a K** G S A F F S W I K R E*
PCL10-b K** G S A L I S Chg I K R E*
PCL10-c K** G S A L I S W I K E*
PCL10-d K** G S Aib L I S W I K R E*
PCL10-e K** G S G L I S W I K R E*
PCL10-f K** G S A L I Me-S W I K R E*
E⁎ refers to fluorescence donor EDANS (5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid) attached to glutamic acid side chain.
K⁎ and K⁎⁎ denotes fluorescence quencher Dabcyl (4-{[4-(dimethyl amino) phenyl] azo} benzoic acid) amidated to lysine side chain and the N-terminus, respectively.
All peptides were synthesized as carboxamide (CONH2) at the C-terminus. The natural and unnatural amino acid substitutions in the parent PCL's are denoted in bold. Cit= L-Citrulline, 1-
Nal = L-1-Naphthylalanine, F(4NO2) = 4-Nitro-L-phenylalanine, Chg = L-cyclohexylglycine, Aib = 2-Aminoisobutyric acid, Me-S = 2-Methyl-L-serine.
a D-Amino acid is denoted in lower case.
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ARPE-19 cells that were cultured on the filters. ARPE-19 cells were cul-
tured as amonolayer on Transwell filters for fourweeks to obtain polar-
ized and differentiated cells as described earlier [40]. The medium was
replaced on both the apical and basolateral compartments twice a
week. After four weeks of culture, the cells were treated with the
cargo containing oligopeptides (5 μM) on the apical side for 1 h (7%
CO2, 37 °C). Subsequently, themediumwas removed from both the api-
cal and basolateral compartments and the cells were washed three
times with PBS. Fresh complete growth medium was added to both
the apical and basolateral compartments. The zero-time point sample
was collected immediately from the basolateral compartment and the
cell culture was continued. Thereafter, samples were collected from
the basolateral compartment at time intervals (8 h, 24 h, 48 h and
72 h) and after each sampling, an equivalent amount of fresh medium
was added to the basolateral compartment. Samples were stored in
low binding Eppendorf tubes at 4 °C.2.8. LC-MS analysis
To identify cargo fragments released in the cells (cell lysate) and by
passive diffusion (basolateral compartment) Section 2.7, three volumes
of cold acetonitrile were added to each sample, vortexed and stored at
room temperature for 1 h. The samples were centrifuged for 10 min at
12,000g to remove precipitates. The supernatant was freeze-dried and
stored at−20 °C for further LC-MS analysis.
For quantitative analysis, cargo peptide fragments with isotope la-
beled amino acidwere used as internal standards (Table 2). The L-valine
residue in the cargo peptide fragment was labeled for this purpose and
the internal standards were calibrated. The cargo peptide fragments
were quantified by comparing the peak area to that of the internal stan-
dards. For this, samples from the cell lysate and the basolateral compart-
ment were spiked with the internal standards before adding the
extraction solvent. Three volumes of cold acetonitrile were added to
each spiked sample, vortexed and kept at room temperature for 1 h.
The samples were centrifuged for 10min at 12,000g to remove any pre-
cipitates. The supernatant was freeze-dried and stored at −20 °C for
further LC-MS analysis.
LC-MS analysiswas performed on anAgilent 1290 UPLC system con-
nected to Agilent 6540 Q-TOF mass spectrometer (Agilent, Waldbronn,
Germany). The instrument was used in positive electrospray ionization
and full scan mode. Prior to the LC-MS analysis, the samples were dis-
solved in 150 μl of 10% ACN containing 0.5% formic acid. Injection vol-
ume was 2 μl and the mobile phases were delivered at a flow rate of
0.4 mL/min using the gradient: 5%–70% ACN on a Kinetex 2.6 μm C18,
100 × 2.1 mm column (Phenomenex, Torrance, CA, USA).The extracted ion chromatogram (EIC) for each peptide frag-
ments obtained from the LC-QTOF/MS run was analyzed using
Agilent Mass Hunter Qualitative Analysis software (Santa Clara, Cal-
ifornia, USA). Each peptide fragment was analyzed using 20 ppm
mass window and peak areas on channels with 2, 3 and 4monoisoto-
pic charges were summed. Sequences of analyzed peptides, their
exact masses and ions used for quantitation are listed in Table 2.
The exact masses of the cargo conjugates and the corresponding
fragments were calculated using UCSF MS-product program
(http://prospector.ucsf.edu).2.9. Computational modeling of cathepsin D - PCL complexes
Structural models of PCL binding to cathepsin D were obtained
using the de novo prediction tool PEP-FOLD3 [42]. Briefly, the en-
zyme-peptide complexes were generated starting from defining a
patch of the interaction site(s). For the native substrate (PCL1) and
other related derivatives, the probable enzyme residues engaged in
interaction with the peptides were defined based on the crystal
structure of the complex of cathepsin D with its inhibitor pepstatin
[43] and an earlier study [44]. Interaction site residues correspond-
ing to positions P2 and P3 of the PCLs (the scissile residues being
P1-P1′; Table 1) were identified as: Ser 80, Gly 225, Thr 226,
Phe 118, Val 230, Met 299, Met 301, Ile 312, Gln 14 and Ser 227.
The method employs a coarse-grained representation to generate
the initial models which are then refined using a Monte Carlo proce-
dure. The best structural model for the enzyme – PCL1 complex
was selected by comparison with the crystal structure of cathepsin
D - pepstatin complex so that the corresponding residues of both
the ligands had the best-fit match.
Molecular visualization and structural superposition were per-
formedwith the UCSF Chimera package [45]. Finally, the best structural
models of the cathepsin D - PCL complexes were subjected to high-res-
olution refinement using the Rosetta FlexPepDock protocol [46,47] and
the top models were utilized for analysis. PCL8 and its close derivative,
PCL8-b were modelled with phenylalanine at P1′ position in-lieu of
nitro-phenylalanine as the programwas limited to account for only nat-
ural amino acid residues. Also, PCL1 was modeled sans the C-terminal
Arg 11 as our assay results showed it to have little impact on enzymatic
cleavage rate and to allow better structural comparison between pep-
tides of similar sequence length. For consideration of interactions be-
tween cathepsin D and the peptides, slightly liberal cut-off distances
were applied considering the macromolecular nature of structures and
the fact that the structural complexes were obtained by computational
methods. Non-conventional interactions were also considered in our
analyses.
Fig. 2. Cytotoxicity of PCLs in ARPE-19 cells. Cells were treated with peptides for 5 h and
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3.1. Peptide cleavage in the RPE cell homogenate
A set of peptide substrates (Table 1) with putative sensitivity to ca-
thepsinDwere subjected to cleavage assay in the ARPE-19 homogenate.
The aim was to utilize these substrates as ‘peptide-based cleavable
linkers’ (PCL) for cargo attachment and controlled release in the RPE
cells as there is cathepsin D activity in the RPE cells [35]. Although the
PCLs were chosen to be sensitive to cathepsin D, they could as well pos-
sibly undergo cleavage by the concerted action of intracellular prote-
ases. The peptides were labeled with a FRET pair (EDANS/Dabcyl) for
monitoring the peptide cleavage using fluorescence (Scheme 3).
The PCL sequences showed varying rates of cleavage (Fig. 1). It is re-
markable that some PCLs are cleaved almost completely in the RPE ho-
mogenate within 1–2 h (e.g. PCL 1, PCL 5), whereas others show
moderate to slow cleavage rates (e.g. PCL 10, 40% in 48 h; PCL 8, less
than 10% in 48 h).cell viability was evaluated with MTT cytotoxicity assay. Data was normalized based on
the viability of untreated cells. Data are represented as mean ± SD (n = 3).3.2. PCL conjugates with cell penetrating peptides
Intracellular delivery depends on the ability to transport the drug
across the plasmamembrane. A set of four CPPs selected from literature
precedence [48–50] were used to construct twelve chimeras (4 CPPs at-
tached to 3 PCLs) by fusing CPPs to the N-terminus of the PCL peptides
(Scheme 2). Based on PCL cleavage rates (Fig. 1), two rapid cleaving
(PCL1, PCL5) and one slow cleaving (PCL10) sequences were chosen
for conjugation with CPPs. The selected PCLs were not toxic to the
ARPE-19 cells (Fig. 2) and were armed with the FRET pair (Dabcyl/
EDANS) to facilitate easy read out of the cleavage assays with the CPP-
PCL chimeras. The CPP-PCL chimeraswere tested for their cleavage pro-
pensity in the ARPE-19 cell homogenate. PCL1 and PCL5 containing chi-
meras cleaved rapidly compared to the PCL 10 (Fig. 3).
No significant changes in the cleavage rates were seen for the CPP-
PCL chimeras as compared to the native PCLs. Strikingly, though, a sig-
nificant difference in the relative degree of cleavage of PCL1 and PCL5
was observed as compared to their conjugated form with CPP1. It is
plausible that CPP1 influences the access of the PCL1 cleavage site by ca-
thepsin D either sterically or by inducing a conformational change. In
the case of CPP1-PCL5, there could be a modest increase in cleavage
rate of PCL5 effected by CPP1 that could result in aggregation leading
to enhanced ‘fluorescence’ [51,52].Fig. 1. Enzymatic assay of PCLs in ARPE-19 cell lysate. PCLs were incubatedwith cell lysate
and fluorescence intensity from EDANS was recorded over time (Ex: 340 nm; Em:
490 nm). Data was normalized to that of free EDANS. Error bars represent mean ±
standard deviations for n = 3.3.3. Uptake of PCL and CPP-PCL peptides into the RPE cells
Fluorescence assisted cell sorting (FACS) analyses were carried out
to determine cellular uptake and subsequent cleavage of the peptides
within cultured ARPE-19 cells. EDANS fluorescence (450/20 band pass
filter) allowed estimation of the cleaved PCL fragments. No EDANS fluo-
rescencewas expected fromnative peptide chimeras due to FRET effect.
The analyses showed increased cellular fluorescence intensity in ARPE-
19 cells for the CPP conjugated PCL chimeras (Fig. 4) as compared to
constructs without the CPPs (Supplementarymaterial, Fig. S2). Interest-
ingly, however, native PCL1 (without any CPP attached) showed signif-
icant cellular uptake (Supplementary material, Fig. S2). This was an
intriguing observation and we decided to include PCL1 in its native
form in further cargo release studies. All CPP-PCL chimeras were non-
toxic in the ARPE-19 cells (Supplementary material, Fig. S3, data
shown only for the two chimeras used for further conjugation with
cargoes).Time (h)











































Fig. 3. Enzymatic cleavage of CPP-PCL chimeras in ARPE-19 cell lysate. The conjugates
were incubated with cell lysate and EDANS fluorescence as a measure of PCL cleavage
was detected at different time points (Ex: 340 nm; Em: 490 nm). Fluorescence of EDANS
increased over time as a result of proteolytic cleavage of PCLs and consequent de-
quenching of EDANS. The fluorescence intensities were normalized based on the total
fluorescence of free EDANS. Error bars represent mean ± standard deviations for n = 3.
Fig. 4.Uptake of CPP-PCL chimeras (5 μM)byARPE-19 cells. Following 1 h of incubation at
37 °C, cells werewashed andmean fluorescence intensity of EDANS in the living cells was
measured by flow cytometry. Mean values of three independent experiments, each
performed in triplicate, are shown. Conjugates CPP1-PCL5 and CPP2-PCl 5 were found to
have toxicity at concentration 5 μM and higher and were not included in the cellular
uptake assay.
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In vitro stability of the CPP-PCL chimeras was tested in ex vivo por-
cine vitreous. All the chimeras were stable in the porcine vitreous for
more than 6 days (Supplementary material, Fig. S4). This is important
because upon intravitreal injection, the PCLs should/need to be chemi-
cally stable in the vitreal environment and be able to release the cargo
only after their cellular entry.3.5. Cargo release from the peptide conjugates
For cargo release studies, two representative chimeric peptideswere
chosen: CPP1-PCL1 (fast cleaving) and CPP1-PCL10 (slow cleaving). The
same CPP was used in both chimeras to enable comparisons of the in-
trinsic cleavage propensity of the PCLs and exclude the effects of the an-
choring CPP sequence. PCL1 was also included in the release studies
since it showed cellular uptake without an anchoring CPP. Two D-Fig. 5.Quantitative estimation of (A) hydrophobic and (B) hydrophilic cargo release inARPE-19
cells were incubatedwith cargo conjugates (5 μM) at 37 °C for 1 h. Following cell lysis, the intra
concentrationswere calculated from the peak area ratio of non-labeled to labeled fragments (in
each. The error bars represent standard deviations between repeats.pentapeptide sequences were chosen as cargoes because they are enzy-
matically stable and afforded easy conjugation at the C-terminus of CPP-
PCL chimeras. This strategy enabled quantitative LC-MS analyses of the
intact D-peptide (cargoes) after their enzymatic release. Lipophilic
(fwpVl: log D=+2.0) and hydrophilic (ynaVl: log D=−2.0) D-penta-
peptide sequences were used as cargo prototypes in six conjugates
(Table 2). The released fragments in the ARPE-19 cells were identified
from whole cell lysates by LC-QTOF/MS analysis. For each cargo, two
fragments were detected, containing one or two carry over residues
from the PCL sequences. The hydrophobic cargo fwpVl was detected
as fragments rfwpVl and KrfwpVl and the hydrophilic cargo ynaVl as
fragments rynaVl and KrynaVl. The detected fragments and their corre-
sponding masses are listed in Table 2.
The released cargo fragments were quantitated in whole cell lysate
after 1 h exposure of the ARPE-19 cells with cargo conjugates. CC-3
and CC-4 showed greater cargo release than CC-5 and CC-6 for both hy-
drophilic and hydrophobic cargoes (Fig. 5A, B). CC-3 and CC-4 contain
PCL1, the fast cleaving linker, whereas CC-5 and CC-6 include the slow
cleaving PCL10. Different levels of cargo release from these conjugates
could be attributed to the PCL sequence.
Released levels of cargo D-peptides from CC-1 and CC-2 were low
(Fig. 5A, B). CC-1 and CC-2 contain only native PCL1 without CPP. This
was an unexpected result because PCL1 showed high cellular uptake
and rapid cleavage in the cell homogenate (Fig. 1 & Supplementary ma-
terial, Fig. S2) using FACS based technique.We postulate that unlike CPP
chimeras, CC1 and CC2 may not be accessible to the enzymes in the in-
tact cells.
In the second experiment, intact RPE monolayer was mimicked.
ARPE-19 cells were cultured on laminin coated filters to a polarized
tight epithelium. The cargo conjugates (CC1–CC6) were placed to
the apical side of the monolayer and sampled from the basolateral
compartment at different time points (Fig. 6A). The results followed
the same trend as seen in the whole cell lysates. Higher amounts of
released cargo fragments were recorded from the basolateral side
after CC-3 and CC-4 administration than from CC-5 and CC-6 (Fig.
6B, C). The cargo fragments gradually accumulated to the basolateral
side of the RPE blood-retinal model. No significant release of cargo
fragments was seen after administration of CC-1 and CC-2 (Fig. 6B,
C). These observations validate that the fast cleaving PCL1 results
in faster cellular cargo release than the slowly cleaving PCL10 in
the case of CPP-PCL conjugates. Apparently, PCL1 without cell pene-
trating peptide does not reach the cleaving enzymes in the RPE
monolayer.cell lysates. Intracellular concentrations of cargo fragmentswere determined after ARPE-19
cellular concentrations of cargo fragments releasedwere estimatedwith LC–MS. Fragment
ternal standard). The results are average values of two repeats with three parallel samples
Fig. 6. (A) Quantitative estimation of cargo fragments from the basolateral chamber in filter cultured ARPE-19 cells (blood-retina-barrier model). Filter cultured ARPE-19 cells were
incubated with cargo conjugates (5 μM) at 37 °C for 1 h. Concentrations of cargo fragments (B) hydrophobic and (C) hydrophilic were determined at different time points by LC–MS.
Fragment concentrations were calculated from the peak area ratio of non-labeled to labeled fragments (internal standard). The results are average values of two repeats with three
parallel samples each. The error bars represent standard deviations between repeats.
Fig. 7. Enzymatic cleavage assay of PCL analogs. Increase or decrease (fold) in the
enzymatic cleavage value relative to the parent peptide at 4 h is shown. Each assay was
performed in triplicate and the average values have been presented.
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cargoes can be transported and released in the intracellular environ-
ment of ARPE-19 cells using PCL linkers. Higher amounts of hydropho-
bic cargoes were seen than the hydrophilic cargo peptide fragments in
the basolateral compartment after administration of similar conjugate
system (i.e. CC-3 vs CC-4 and CC-5 vs CC-6) (Fig. 6B, C). It seems that
the hydrophobic cargo is released faster than the hydrophilic cargo
within the cells, the released hydrophobic cargo probably also perme-
ates faster across the plasma membrane to the basolateral
compartment.
3.6. Structure-activity relationship of PCLs
To understand the structural requirements of PCLs for cathepsin D
mediated cleavage, analogs of the parent PCLs with natural and unnat-
ural amino acid residues were studied using enzymatic assays and com-
putational modeling. Previous studies indicated the preference for
certain amino acids at or near the scissile bond (P1, P1′, P2, P2′ and
P3, P3′ and P5, P5′) positions [44,53,54]. Thus, several analogs of fast
cleaving (PCL1) and slow cleaving (PCL8, PCL10) with natural and un-
natural amino acid substitutions were subjected to cathepsin Dmediat-
ed enzymatic cleavage assay in ARPE-19 homogenate (Table 3).
The effects of amino acid substitutions are expressed as relative in-
crease or decrease in the enzymatic cleavage value of the PCL analogs
at a certain time point (4 h) as compared to the parent PCL. The results
are depicted as relative fluorescence unit (% EDANS) in Fig. 7. Notably,
analogs PCL1-b and PCL1-c showed a significant reduction in cleavage
rates as compared to the parent PCL1. The analogs of the moderatelycleaving PCL10 namely, PCL10-a and PCL10-d retained their enzymatic
activity; in fact, they showed a modest increase. The results suggest
that the substitutions at P1-P1′ sites in PCL10-a and at the P2 site in
PCL10-d are well tolerated with slightly increased enzymatic activity.
The computational model supports the notion that increased hydro-
phobicity at the P2 sitemight increase the peptide's sensitivity to cleav-
age. Residues Met 299, Met 301, Val 230, Leu 228, Ile 312 and Thr 226
present a hydrophobic pocket for interaction with the side chains of
the residue at P2. In the case of PCL1, hydrophobic interaction of the
Fig. 8. Non-covalent interactions of PCL1 (green) at the cathepsin D (grey) catalytic site.
PCL1 residues are labeled in green. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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Met 299 and Met 301 is significant. In addition, the backbone of Leu 5
is stabilized by a weak C\\H⋯O hydrogen bond from the donor Ser
80. Interestingly, the P1 site residue, Phe 6 makes contact with the cat-
alytic residues Asp 33 and Asp 223 via two weak non-covalent interac-
tions; lone-pair(anion)⋯π and the C\\H⋯O hydrogen bond. Phe 6 is
stabilized by a network of weak non-conventional interactions and a
conventional H-bond (Table 4). Both the P1′ and P2′ residues of PCL-1,
namely Phe 7 and Arg 8 mediate contacts with cathepsin D through a
combination of hydrophobic forces, weak non-covalent interactions
and strong H-bond. In particular, Phe 7 is an acceptor of two C\\H⋯π
contacts with the enzyme residue Ile303 and the side chain of Arg 8 is
stabilized by two strong N\\H⋯O hydrogen bonds. Overall, a plethora
of weak interactions, hydrophobic forces and a few strong hydrogen
bonds form the basis of peptide recognition and catalysis (Fig. 8, Table 4).
4. Discussion
Current therapeutic approaches to deliver drugs to the retina and
choroid utilize local intravitreal injections. Frequent injections are not
desirable for reasons of patient compliance and burden to the
healthcare. Thus, a significant challenge is tomaintain therapeutic levels
of the drugs for prolonged periods [29,55]. Duration of drug action can
be increased with controlled release formulations (e.g. intraocular im-
plants), but these technologies do not augment delivery of poorly per-
meating drugs to the intracellular space. Often development projects
are discontinued due to the inadequate tolerance of the carriermaterials
in the eye. New safer delivery systems for prolonged and intracellular
drug delivery are needed in the field of retinal and choroidal drug
treatment.
The RPE is a key therapeutic target cell in several diseases, e.g. viral
infections, dry AMD, proliferative vitreoretinopathy and some retinal
degenerations [56–58]. Also, the choroid is an important drug target,
for example in the neovascular conditions (e.g. the wet form of AMD).
For these reasons, we envisioned a strategy for intracellular drug release
within the RPE cells with enzymatically cleaving peptide linkers. The re-
leased drug could target intracellular components or alternatively theTable 4
Non-covalent interactions between PCL1 and cathepsin D residues in the structuralmodel










P1 Phe 6/HD1 Thr 226/N 2.7/145.3 C\\H⋯N
Phe 6/HD1 Thr 226/OG1 3.3/130.1 C\\H⋯O
Phe 6/HE1 Gly 225/O 2.7/121.8 C\\H⋯O
Phe 6/centroid Asp 33/OD2 3.7 lp(anion) ⋯π
Phe 6/1HB Asp 223/OD2 3.0/145 C\\H⋯O
Phe 6/1HB Thr 226/OG1 2.8/127.5 C\\H⋯O
Phe 6/H Thr 226/OG1 2.0/150.8 N\\H⋯O
Phe 6/O Ile 312/3HD1 2.8/144.1 O⋯H\\C
Phe & HA Tyr 78/O 3.0/144.1 C\\H⋯O
P2 Leu 5/CD1 Met 301/SD 3.5 Hydrophobic
Leu 5/CD1 Met 299/SD 4.6 Hydrophobic
Leu 5/O Ser 80/2HB 2.3, 157.6 O⋯H\\C
Leu 5/CD2 Thr 226/CG2 3.6 Hydrophobic
Leu 5/CD2 Leu 228/N 3.5 Van der Waals
Leu 5/3HD1 Met 301/SD 2.9/130.4 C\\H⋯S
P1′ Phe 7/H Tyr 78/O 2.0/122.7 N\\H⋯O
Phe 7/O Tyr 78/HA 3.3/115.6 O⋯H\\C
Phe 7/2HB Tyr 78/O 2.7/123.3 C\\H⋯O
Phe 7/centroid Ile 303/3HG2 3.2 C\\H⋯π
Phe 7/centroid Ile 303/2HD1 3.1 C\\H⋯π
Phe 7/HE1 Ser 307/OG 2.3/144.1 C\\H⋯O
P2′ Arg 8/1HB Ser 36/N 3.2/141.1 C\\H⋯N
Arg 8/1HB Ser 36/OG 3.3/147.9 C\\H⋯O
Arg 8/1HG Ile 134/O 3.3/123.8 C\\H⋯O
Arg 8/HE Ser 36/OG 2.0/149.1 N\\H⋯O
Arg 8/2HH1 Val 136/N 2.7/148.9 N\\H⋯N
Arg 8/1HH2 Ser 36/OG 1.9/140.9 N\\H⋯ORPE cells might form a depot of the released cargo that diffuses to the
surrounding tissues (e.g. neural retina, choroid) (Fig. 6). The rate of
cargo release from the RPE cells can be controlled by modulating the
cleavage of PCLs. The strategy draws a parallel with the approach of
transfecting the corneal epithelium and the RPE for continued expres-
sion and secretion of bioactive agents [59,60] but with the advantage
that exogenous molecules could be released with control based on PCL
sequence.
For the purpose of intracellular cargo release by enzymatic cleavage,
PCL sequenceswith varying sensitivity to cathepsinDwere selected. Ca-
thepsin D, a lysosomal enzyme, has high expression levels in RPE cells
but not present in the vitreous [35]. Increased activity of cathepsin D
with aging has been reported [61]. Intracellular uptake was facilitated
by conjugating CPPs with PCLs harboring cargo. D-pentapeptide cargoes
were chosen for ease of synthesis, resistance to proteolytic cleavage to
facilitate detection and easymanipulation of sequence to effect changes
in physicochemical properties of the cargo prototypes (hydrophobic/
hydrophilic). Our studies identified PCLs and CPP-PCL chimeras that
showed intracellular localization and differential rates of cargo release
in the ARPE-19 cells. The chimeras were non-toxic to the ARPE-19
cells and stable in porcine vitreous ex vivo. The fast cleaving CPP-PCL
chimeras released the cargo inside the ARPE-19 cells for at least three
days as the cleavage seems to continue during the time period 0–72 h.
It is likely that the slow cleaving CPP-PCL chimeras release the cargo
much longer than 72 h because the cleavage rate was slow. Although
it is difficult to predict the total duration of complete release, depending
on the initial dosing the strategy seems to have the potential to release
the cargo for at least weeks. Obviously, slow release rates are desirable
for highly potent compounds that are capable of exerting their actions
at low concentrations. A fast releasewould be preferable for compounds
that act by turning on some biochemical mechanism that will then pre-
vail for a long time. Our estimates show that for ‘nanomoles’ of the cargo
within the RPE cells, ‘picomoles’ of passively diffusing cargo from the
RPE (to the basolateral compartment) is detected over a time period
of 72 h. Consideringmoderate recovery loss due to technical limitations,
this still holds promise for sustained release over a long period of time.
Earlier studies on intracellular cargo delivery relied on fluorescence
microscopy or flow cytometry to establish cargo delivery [62–66].
Other studies too have used secondary read out effects such as anti-pro-
liferative effects of cancer drugs [67] or changes in the protein expres-
sion after siRNA delivery [68] as validation of cargo delivery. In our
present study, we demonstrate accurate quantification of intracellular
cargo release using LC-MS, like we did previously for liposomes in the
cancer cells [69]. To the best of our knowledge, this is the first report
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in the intracellular and extracellular space. We postulate that themeth-
odology has general applicability to other cell types and therapeutic
agents.
To understand the structural requirements of the PCLs we carried
out computational modeling. The enzyme-PCL complexes revealed the
significance of weak non-covalent interactions at the catalytic site.
This is in tune with the growing realization of the importance of such
forces in biomolecular recognition and activity [70–73]. It was intrigu-
ing to find a rationale for the lack of enzymatic cleavage of PCL8
(GSPIVF⁎NphRL). This was particularly so in light of the fact that a close-
ly related peptide, PCL8-b (KPIVF⁎NphRL), in an earlier study showed
moderate levels of substrate activity [44]. We compared the structural
models of PCL1, PCL8 and the related PCL8-b in complex with cathepsin
D (Fig. 9). All three peptides seem to be able to present their epitopes for
enzymatic cleavage and the striking differences arise from the position-
ing of the long side-chain of the N-terminus Lys 2/Lys 1 (PCL1/PCL8-b).
In the PCL-1 complex, Lys 2 backbone is stabilized by cathepsin D by vir-
tue of a strong donor H-bond (N\\H⋯O) from Gln 14 and a few weak
donor H-bonds (N\\H⋯N & C\\H⋯O) from Gln 14 and Ala 13. Even
though the long side chain of Lys 2 does not contact the enzyme resi-
dues, several possible rotamers are feasible that enhances the accessible
conformational space of the Lys 2 side chain. The lysine side chain is
thus capable of forming both hydrophobic, weak non-covalent interac-
tions and hydrogen bonds with neighboring enzyme residues. A similar
possibility exists for the N-terminus Lys 1 in the PCL8-b complex. How-
ever, in PCL8, the short side chain of serine has only a few rotamers and
consequently a limited accessible conformational space. These factors
reduce the chance of stabilizing contacts of the Ser 2 with neighboring
enzyme residues. Apparently, the long side chain of the Lys 2 residue an-
chors the peptides (PCL1, PCL8-b) within the catalytic site of cathepsin
D facilitating the register of the cleavable epitopes for catalysis.
The structural models also provide a rationale for the 70-fold loss
of catalytic activity in PCL1-c, wherein the P1 and P1′ residues are
substituted with tryptophan. A comparison of the top models for
both the complexes, PCL1 and PCL1-c with cathepsin D (Fig. 10A, B)
seem to suggest that the introduction of Trp-Trp results in conforma-
tional mobility of the peptide. This necessitates a conformational rear-
rangement of the enzyme with the possibility of disturbing theFig. 9. Superposition of structural models of PCL1 (green), PCL8 (pink) and PCL8-b
(orange) at the catalytic site of cathepsin D (grey). Peptide sites are labeled in green
colour. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)delicate interactions at the active site. A similar rationale might hold
true for the 300-fold loss of activity in the napthylalanine substituted
peptide (PCL1-b).
The residence time of injected drugs in the vitreous depends on the
molecular size [74]. Retention of peptides is less than six days indicating
that the peptide chimeras would not release the cargo prematurely
within the vitreous humor. Cargo release is expected to take placewith-
in the RPE cells where we determined the release kinetics for 72 h. Fast
cleaving PCLs released cargomuch faster than the slow cleaving PCLs in-
dicating that it would take longer to release whole cargo from the slow
cleaving PCLs. The release will last for much longer than 72 h because
the quantity of the released peptides within the RPE cells was esti-
mated to be nanomoles (Fig. 5) whereas picomole amounts were de-
tected in the extracellular space (Fig. 6). In the case of specific drugs,
these dosing considerations are complicated and affected by many
factors. For subconjunctival administration 1–2 weeks' dosing inter-
vals is fine, while one month or longer is preferable for intravitreal
administration. Different drugs have specific effective concentra-
tions and local clearance rates that determine the required rate of
delivery. Finally, some drugs require constant drug exposure, but
some molecules turn on the biochemical event and result in activity
of weeks after local drug delivery [75]. We have shown here a new
concept for intracellular drug release in the RPE. Future studies will
shed light on how this concept could be utilized for specific drugs
and treatments.
Ocular drug delivery systems often exhibit desirable release
properties, but still lack translational success. Among other aspects,
onemajor cause that limits their application in vivo is toxicity arising
from synthetic polymeric materials, their degradation products or
carry-over additives from drug formulation. In other instances, phys-
icochemical properties of the drug molecules were exploited to form
depots for sustained release, but this is applicable only in specific
cases [76,77]. We report here a peptide-based delivery system that
utilizes the cellular environment of the RPE cells to act as a reservoir
for controlled release of cargo fragments to the extracellular/choroi-
dal space. The peptide based delivery system is non-toxic, stable in
porcine vitreous and does not rely on the physicochemical proper-
ties of a particular drug molecule for binding to cellular components.
The efficacy of cargo delivery would depend upon the mechanism of
cellular uptake and consequently lysosomal trafficking. Differential-
ly cleaving linkers offer the advantage of modulating the rate of
cargo release intracellularly thereby facilitating drug delivery to
the intracellular targets. To the best of our knowledge, this is the
first report to demonstrate the utility of RPE cells to act as a reservoir
for controlled release of exogenous drugs. Small molecule drugs are
rapidly cleared within the vitreous and the strategy to utilize the
RPE cells for controlled release would increase the duration of drug
activity. Although small molecules and peptides are likely to diffuse
out from the RPE cells (depot action that we have highlighted), deliv-
ery of therapeutic proteins for targeting intracellular components
too can be an exciting prospect [36].5. Conclusions
We highlighted a peptide-based strategy for sustained drug release
utilizing the intracellular space as a depot in the ocular context. While
in most cases drug release from intracellular depots, such as nanoparti-
cles, is spontaneous and poorly controlled, our approach of using differ-
entially cleaving peptide sequences as linkers to the cargo drug allows
pre-designed control of the release rates. Also, the strategy does not de-
pend on the physicochemical properties of a particular drug and thus
presents a broad applicability as long as the drug can be linked to the
peptides. Specific cell type targeting moieties or grafting of the PCLs
onto biodegradable polymers may further future applications of this
technology.
Fig. 10. Superposition of top ten structural models (A) PCL1 and (B) PCL1-c at the catalytic site of cathepsin D (grey).
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